Araceli Biosciences

Araceli Biosciences launched the Endeavor high-content analysis platform in January 2021.

Clairvoyance maximizes high-content data potential for users of the Endeavor platform.

BPAE cells with mitochondria (red, MitoTracker Red CMXRos), actin (green, Alexa Fluor 488 Phalloidin), and DNA (blue, DAPI) stains. Source: FluoCells slide 1.

Home » HCI and Subcellular Analysis of Autophagy in 15-30 Minutes per Plate

Home » High Content Is Now High Throughput: Subcellular Analysis of Autophagy

Home » Araceli Biosciences Established to Accelerate Drug Discovery and Research

Home » Araceli Biosciences Introduces Matt Beaudet as New President and CEO

Home » Araceli Biosciences Moves to a New Location

Araceli prides itself in bringing a diverse group of individuals together for a common goal: faster, easier, and better drug discovery

Araceli Biosciences is on a mission to transform therapeutic discovery through technologies built for speed, precision, and impact.

Araceli Biosciences secures **$4.5 million** to commercialize instruments and software replacing animal testing with human-cell models, AI, and simulations. The Portland-based startup supports **New Approach Methodologies (NAMs)**, which advocates claim improve drug efficacy and reduce costs by avoiding irrelevant animal results. Half of the **top 20 pharmaceutical companies** already use its technology, and the company has expanded globally with offices in the **Bay Area, Boston, London, and Berlin**. Investors include animal welfare advocate **Jeff Swickard** and Fluke Venture Partners, bringing total funding to **$18.76 million** since its 2023 launch as a Phoseon Technology spinoff.

Nov 2026GeekWireNews article

Araceli Biosciences secures $4.5 million in financing, with investor Jeff Swickard joining to support its mission. The company develops human cell science alternatives to replace animal testing. This funding aims to advance its technology and contribute to Oregon’s growing biotech sector.

Nov 2026PR NewswireNews article

Endeavor joins Ginkgo Bioworks’ Nebula program to integrate its **Lab-in-the-Loop** technology into biomanufacturing workflows. The collaboration aims to accelerate iterative testing and optimization of biological processes. Ginkgo Bioworks’ Nebula provides access to its foundry model for startups and researchers developing advanced biotech solutions.

Oct 2026Araceli BiosciencesNews article

Araceli Biosciences and Ginkgo Bioworks integrate high-speed cellular imaging into Nebula’s **Lab-in-the-Loop** platform. The collaboration leverages Ginkgo’s **Endeavor** system to deliver rapid, continuous high-content cellular data generation. This expands automated, real-time lab workflows for biotech research and development.

Oct 2026PR NewswireNews article